RxDoctor Payments Data

Erin Bardin, MD

Dermatology · Fairhope, ALNPI 1871785279

Payments from drug & device makers

$5,515in general payments, 2019–2025

Across 289 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sun Pharmaceutical Industries Inc.$435
  • Galderma Laboratories, L.p.$378
  • Lilly USA, LLC$357
  • Mayne Pharma Commercial LLC$351
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$331
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,41598%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,515 in reported general payments places this provider in the 50th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama

Medicare billing

Part B allowed, 2024
$278,101
Medicare patients
999
Services billed
4,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab15$125,086
OtezlaApremilast16$77,280
Dupixent SyringeDupilumab12$44,726
Clobetasol Propionate147$6,954
Fluocinonide35$1,295
Triamcinolone Acetonide112$1,167
Metronidazole21$1,165
Ketoconazole90$1,134
Gentamicin Sulfate11$669
Ciclopirox24$463
Nystatin36$434
Econazole Nitrate14$430
Clindamycin Phosphate14$288
Mupirocin37$261
Dutasteride20$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$161$77,28016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 168 dermatology providers in Alabama.

Other dermatology in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →